Barry E. Greene — President at Alnylam Pharmaceuticals

Mr. Barry E. Greene has been the President at Alnylam Pharmaceuticals, Inc. since December 12, 2007 and served as its Chief Operating Officer October from 2003 to September 19, 2016. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries. Mr. Greene joined Alnylam in 2003 and has over 15 years of experience in the healthcare industry. He served as the Principal Financial Officer and Principal Accounting Officer of Alnylam Pharmaceuticals Inc. He served as Treasurer of Alnylam Pharmaceuticals Inc. since February 2001 until September 2003. From February 2001 to September 2003, he served as General Manager of Oncology for Millennium Pharmaceuticals Inc., where he led its global strategy and execution for its oncology business. From January 2000 to February 2001, he served as an Executive Vice President and Chief Business Officer of Mediconsult.com. From February 1997 to December 2001, he served as Vice President of Marketing and Customer Services at AstraZeneca and also served as its Vice President of Strategic Integration. He was a Partner of Andersen Consulting with leadership responsibility in the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene has been a Director at Acorda Therapeutics, Inc. since January 8, 2007 and Karyopharm Therapeutics Inc. since January 2013. He has been Lead Independent Director at Karyopharm Therapeutics Inc. since January 2015. Mr. Greene served as a Director at Regulus Therapeutics Inc., from January 2009 to November 5, 2012. Mr. Greene served as a Director of Ambrx, Inc. since January 2014. He served as a Director of Intercept Pharmaceuticals, Inc. from February 8, 2011 to August 9, 2012. He served as a Director of Regulus Therapeutics LLC since November 2007. He is a Senior Scholar at Duke University's Fuqua School of Business. Mr. Greene received a BS in Industrial Engineering from the University of Pittsburgh.